Planforge Introduces Product Maturity Level Tracking with New Gate Management Option
13.2.2025 14:30:00 CET | Business Wire | Press release
Release 25 Also Introduces First GenAI-Powered Assistant Features and Configurable Portfolio Dashboards
Planforge today announced Planforge 25, the latest release of its industry-leading project work management software. The new version introduces the Gate Management Option (GMO), an optional module developed specifically to help track the product maturity level for development projects. With version 25, Planforge also ships their first GenAI-powered assistant features as announced late last year. The release also features more configurable portfolio dashboards.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250213182628/en/

Planforge 25: New Gate Management Option enables seamless product maturity tracking in development projects. (Graphic: Business Wire)
Gate Management for Development Projects
With its new Gate Management Option, Planforge builds a bridge between development processes and projects by directly integrating support for process gates into project planning. A process gate is a key decision point in a workflow where progress is evaluated to ensure criteria are met before moving to the next phase. Gates are uniquely defined on the project pipeline stage level, and can then be used in project templates and plans together with progress criteria and due dates.
Process gate criteria are based on work packages (WP) and target progress levels per WP. Therefore, the maturity level per criterion can be automatically derived based on actual WP progress. Process gate maturity levels are in turn aggregated based on criteria progress levels. Also target dates for process gates can be automatically monitored based on actual versus planned finish dates of their linked work packages.
"In the technology and automotive industries, gate management today involves a lot of manual work, as project plans are not integrated with process gates in any way," said Gerald Aquila, founder & CEO of Planforge. "With Planforge 25, we are changing the game: by directly reusing existing actual project management data for monitoring and controlling process gates we can not only save many hours of work, but also cut administrative costs significantly."
Additionally, Planforge now integrates a simple but powerful gate review process where go/no-go decisions, gate revisions, and required measures can be easily tracked in a revision-safe way. This allows for early warnings and delivers more transparency and more insightful KPIs. All gate-related information is clearly summarised in dedicated new views for gates planning and controlling, covering single and multiple projects alike.
First Assistant Features of GenAI Initiative
Planforge 25 further introduces the first assistant features of the company’s broader GenAI initiative. For instance, project managers can ask the system for suggestions for SMART (specific, measurable, achievable, realistic and time-bound) project objectives based on the current project description and additional related meta data such as linked ideas. These functions are context-sensitive, directly embedded in the main user interface (in this case, the project charter) and currently powered by OpenAI's ChatGPT.
Configurable Portfolio Dashboards
After introducing custom KPIs and configurable KPI overviews last year, Planforge 25 now also makes portfolio dashboards configurable. Just like for the KPIs view, users can now easily configure the displayed widgets via drag and drop per portfolio.
Availability
Planforge is free for up to four users. Larger teams can test the project work management software via a free 30-day trial. For more information or to be among the first to try the new Gate Management Option, please contact the Planforge sales team at info@planforge.io.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250213182628/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom